CHEK - Check-Cap Ltd.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
3.1500
-0.0200 (-0.63%)
At close: 3:59PM EST
Stock chart is not supported by your current browser
Previous Close3.1700
Open3.2100
Bid1.28 x 900
Ask3.44 x 900
Day's Range3.1500 - 3.4403
52 Week Range3.0820 - 19.7800
Volume34,513
Avg. Volume73,874
Market Cap16.789M
Beta (3Y Monthly)-1.12
PE Ratio (TTM)N/A
EPS (TTM)-3.08
Earnings DateMar 7, 2019 - Mar 11, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est14.00
Trade prices are not sourced from all markets
  • GlobeNewswire28 days ago

    Analysis: Positioning to Benefit within Autoliv, Science Applications International, Trecora Resources, Ardmore Shipping, Check-Cap, and Sharps Compliance — Research Highlights Growth, Revenue, and Consolidated Results

    NEW YORK, Nov. 13, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Check-Cap Reports Third Quarter 2018 Financial Results
    PR Newswirelast month

    Check-Cap Reports Third Quarter 2018 Financial Results

    Announced Interim Results from Post-CE Approval Study of C-Scan® Announces Update on Scheduled Initiation of U.S. Pilot Study ISFIYA, Israel , Nov. 5, 2018 /PRNewswire/ --  Check-Cap Ltd. (the "Company" ...

  • PR Newswire2 months ago

    Check-Cap Announces IDE Submission to FDA for Its C-Scan® System

    If Approved, U.S. Pilot Study Anticipated to Commence in 4Q 2018 ISFIYA, Israel , Oct. 9, 2018 /PRNewswire/ --  Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK) (NASDAQ: ...

  • Check-Cap Receives Approval From the Israeli Ministry of Health to Initiate Commercial Sales in Israel of its C-Scan® System
    PR Newswire3 months ago

    Check-Cap Receives Approval From the Israeli Ministry of Health to Initiate Commercial Sales in Israel of its C-Scan® System

    ISFIYA, Israel, Sept. 5, 2018 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (CHEK) (CHEKW) (CHEKZ), a clinical-stage medical diagnostics company engaged in the development of C-Scan®, an ingestible capsule for preparation-free, colorectal cancer (CRC) screening, today announced it has received approval from the Israeli Ministry of Health, the Medical Device Division (known as "AMAR"), to initiate commercial sales in Israel of the C-Scan system that received CE Mark approval in January 2018. Alex Ovadia, Chief Executive Officer of Check-Cap, commented, "We are excited to receive approval from the Israeli Ministry of Health to initiate commercial sales in Israel of our C-Scan system.

  • PR Newswire3 months ago

    Check-Cap Announces Promising Interim Results from its Ongoing Post-CE Approval Study of C-Scan® System Version 3

    ISFIYA, Israel, Sept. 4, 2018 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (CHEK) (CHEKW) (CHEKZ), a clinical-stage medical diagnostics company engaged in the development of C-Scan®, an ingestible capsule-based device for preparation-free, colorectal cancer (CRC) screening, today announced the interim results for its post-CE approval study of the C-Scan system Version 3. Data from the multi-center clinical investigation showed promising results for detecting patients with polyps in an un-prepped colon. The objective of the study is to assess safety and clinical performance of the C-Scan system Version 3 in detecting patients with polyps.

  • Check-Cap Announces Participation at the 20th Annual Rodman & Renshaw Global Investment Conference
    PR Newswire3 months ago

    Check-Cap Announces Participation at the 20th Annual Rodman & Renshaw Global Investment Conference

    ISFIYA, Israel, Aug. 29, 2018 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (CHEK) (CHEKW) (CHEKZ), a clinical stage medical diagnostics company engaged in the development of C-Scan®, an ingestible capsule-based device for preparation-free colorectal cancer screening, today announced it will be featured as a presenting company at the 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC.  The conference is being held on September 4-6, 2018 at the St. Regis New York Hotel in New York City. If you are an institutional investor, and would like to attend the Company's presentation, please click on the following link (www.rodmanevents.com ) to register for the conference. Once your registration is confirmed, you will be prompted to log into the conference website to request a one-on-one meeting with the Company.

  • Check-Cap Reports Second Quarter 2018 Financial Results
    PR Newswire4 months ago

    Check-Cap Reports Second Quarter 2018 Financial Results

    ISFIYA, Israel , July 31, 2018 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK) (NASDAQ: CHEKW) (NASDAQ: CHEKZ), a clinical stage medical diagnostics company ...

  • ACCESSWIRE5 months ago

    Free Research Reports on DexCom and Three More Medical Research Stocks

    Stock Research Monitor: CGIX, CHEK, and EXAS LONDON, UK / ACCESSWIRE / July 12, 2018 / If you want a free Stock Review on DXCM sign up now at www.wallstequities.com/registration . Today's research on WallStEquities.com ...

  • ACCESSWIRE6 months ago

    Check-Cap to Present at the 8th Annual LD Micro Invitational

    LOS ANGELES, CA / ACCESSWIRE / May 29, 2018 / Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK, CHEKZ, CHEKW), a clinical-stage medical diagnostics company engaged in the ...

  • ACCESSWIRE7 months ago

    Complimentary Technical Snapshots on Bruker and Three More Medical Research Stocks

    Research reports have been issued by WallStEquities.com on BioTelemetry Inc. (NASDAQ: BEAT), Bruker Corp. (NASDAQ: BRKR), Cancer Genetics Inc. (NASDAQ: CGIX), and Check-Cap Ltd (NASDAQ: CHEK). Companies in the Medical Laboratories and Research category is very small from a dividend perspective.

  • Check-Cap Announces Publication of CE Mark Multicenter Clinical Study Results on C-Scan® in Gut
    PR Newswire7 months ago

    Check-Cap Announces Publication of CE Mark Multicenter Clinical Study Results on C-Scan® in Gut

    ISFIYA, Israel, May 22, 2018 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (CHEK) (CHEKW) (CHEKZ), a clinical stage medical diagnostics company engaged in the development of C-Scan®, an ingestible capsule preparation-free, colorectal cancer screening, today announced that the results of its multicenter clinical study that examined C-Scan safety and efficacy (compared to FIT and colonoscopy) for polyp detection confirmed by ensuing colonoscopy, which was submitted for capsule CE Mark, received in January 2018, has been published in Gut, an official peer-reviewed journal of the British Society of Gastroenterology. The article, entitled "A Novel Prep-Less X-Ray Imaging Capsule for Colon Cancer Screening: A Feasibility Study," reported that in 45 analyzed patients, capsule and FIT sensitivity (ability to correctly identify polyps) were 44% and 37%, respectively, with capsule sensitivity increasing to 78% when 50% of the colon surface area was imaged and a linear correlation was observed between imaged area and sensitivity.

  • Check-Cap Reports First Quarter 2018 Financial Results
    PR Newswire7 months ago

    Check-Cap Reports First Quarter 2018 Financial Results

    ISFIYA, Israel , May 17, 2018 /PRNewswire/ --Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK) (NASDAQ: CHEKW) (NASDAQ: CHEKZ), a clinical stage medical diagnostics company ...

  • Check-Cap Announces Closing of $20.2 Million Public Offering and Full Exercise of the Underwriter's Option to Purchase Additional Securities
    PR Newswire7 months ago

    Check-Cap Announces Closing of $20.2 Million Public Offering and Full Exercise of the Underwriter's Option to Purchase Additional Securities

    ISFIYA, Israel, May 8, 2018 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK; CHEKW; CHEKZ), a clinical-stage medical diagnostics company engaged in the development of C-Scan®, an ingestible capsule for preparation-free, colorectal cancer screening, today announced the closing of its previously announced underwritten public offering of 3,189,381 units, with each unit consisting of one ordinary share (or ordinary share equivalent) and one Series C warrant to purchase one ordinary share, along with the exercise in full by the underwriter of its option to purchase an additional 478,407 ordinary shares and Series C warrants to purchase up to 478,407 ordinary shares.

  • Is Check-Cap Ltd (NASDAQ:CHEK) Undervalued?
    Simply Wall St.7 months ago

    Is Check-Cap Ltd (NASDAQ:CHEK) Undervalued?

    Check-Cap Ltd (NASDAQ:CHEK), a medical equipment company based in Israel, saw a significant share price rise of over 20% in the past couple of months on the NasdaqCM. As aRead More...

  • ACCESSWIRE8 months ago

    Today’s Research Reports on Stocks to Watch: Check-Cap and EyePoint Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / April 25, 2018 / Shares of Check-Cap and EyePoint Pharmaceuticals both experienced some unusual activity in Tuesday trading with both stocks seeing significant gains on high ...

  • PR Newswire8 months ago

    Check-Cap Regains Compliance With Nasdaq Minimum Bid Price Requirement

    CHEKW), a clinical-stage medical diagnostics company engaged in the development of C-Scan®, an ingestible capsule for preparation-free, colorectal cancer screening, today announced that it has received notification from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq") that it has regained compliance with Nasdaq Listing Rule 5550(a)(2), which concerns minimum bid price listing requirements.  As previously announced, Check-Cap had been notified by Nasdaq that its ordinary shares failed to maintain a minimum bid price of $1.00 over 30 consecutive business days as required by the Listing Rules of The Nasdaq Stock Market.

  • Check-Cap Files Annual Report for the Year Ended December 31, 2017
    PR Newswire8 months ago

    Check-Cap Files Annual Report for the Year Ended December 31, 2017

    ISFIYA, Israel , April 5, 2018 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK, CHEKW), a clinical stage medical diagnostics company developing a capsule-based ...

  • PR Newswire8 months ago

    Check-Cap Reports Fourth Quarter and Full Year 2017 Financial Results

    Announces the achievement of key validation milestones in C-Scan® system clinical and regulatory pathway ISFIYA, Israel , April 4, 2018 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") ...

  • Check-Cap Initiates EU Post Approval Study Using Advanced C-Scan®
    PR Newswire9 months ago

    Check-Cap Initiates EU Post Approval Study Using Advanced C-Scan®

    Advanced C-Scan Demonstrated Significant Improvement in Average Colon Imaging Coverage in Interim Clinical Evaluation ISFIYA, Israel , March 12, 2018 /PRNewswire/ -- Check-Cap Ltd. (the "Company" ...

  • Check-Cap Appoints Alex Ovadia as Chief Executive Officer
    PR Newswire9 months ago

    Check-Cap Appoints Alex Ovadia as Chief Executive Officer

    Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK, CHEKW), a clinical-stage medical diagnostics company engaged in the development of C-Scan®, an ingestible capsule for preparation-free, colorectal cancer screening, today announced the appointment of Alex Ovadia as Chief Executive Officer effective immediately. Prior to this appointment, Mr. Ovadia served as Check-Cap's Chief Operating Officer, Vice President of Research and Development and Israeli site manager since 2013. He succeeds William (Bill) Densel, who will provide support to complete a seamless transition. Mr. Ovadia brings more than 25 years of experience leading global operations, in addition to worldwide management of complex projects at Philips Healthcare – CT Systems, as a member of Philips Medical Israel management, and at Elbit Systems, a large international defense company, where he held various positions with increased responsibilities.

  • Check-Cap Announces Receipt of Nasdaq Minimum Bid Price Notification
    PR Newswire11 months ago

    Check-Cap Announces Receipt of Nasdaq Minimum Bid Price Notification

    ISFIYA, Israel and BOSTON, Jan. 19, 2018 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK, CHEKW), a clinical-stage medical diagnostics company engaged in the development of C-Scan®, an ingestible capsule for preparation-free, colorectal cancer screening, today announced that the Company received a letter from Nasdaq (the "Letter"), indicating that the Company is not in compliance with the minimum bid price requirement for continued listing set forth in Listing Rule 5550(a)(2) which requires listed securities to maintain a minimum bid price of $1.00 per share. The Letter has no immediate effect on the Company's Nasdaq listing or the trading of its ordinary shares. According to the Letter, the Company has 180 calendar days, or until July 17, 2018, to regain compliance with the minimum bid price requirement. The Company can regain compliance, if at any time during this 180 day period, the closing bid price of its ordinary shares is at least $1 for a minimum of ten consecutive business days, in which case the Company will be provided with a written confirmation of compliance and this matter will be closed.  If the Company cannot demonstrate compliance by the end of the grace period, the Nasdaq's staff will notify the Company that its ordinary shares is subject to delisting.

  • Check-Cap Receives CE Mark Approval for C-Scan®
    PR Newswire11 months ago

    Check-Cap Receives CE Mark Approval for C-Scan®

    ISFIYA, Israel and BOSTON, Jan.10, 2018 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (CHEK) (NASDAQ: CHEKW), a clinical-stage medical diagnostics company engaged in the development of C-Scan®, an ingestible capsule for preparation-free, colorectal cancer screening, today announced it has received CE Mark approval for the C-Scan system. The C-Scan system offers an alternative to current colon cancer screening methods that require laxative preparation and invasive endoscopic procedures. C-Scan is designed to improve the patient experience and increase the number of adults screened by eliminating procedural requirements frequently cited as barriers to adherence to screening guidelines such as bowel preparation, fasting, and sedation.